Stocks in Action USA: Summit Therapeutics, J.M. Smucker, and Abercrombie & Fitch.
Reading Time: 3 minutes
Summit Therapeutics (SMMT) delivers strong cancer data: Ivonescimab significantly extends progression-free survival! Summit Therapeutics is making positive headlines with new Phase 3 data: In the global HARMONi study, the combination of Ivonescimab and chemotherapy extended the median progression-free survival (PFS) for patients with EGFR-mutant, advanced non-small cell lung cancer to 6.8 months, compared to 4.4 months with chemotherapy plus placebo. The hazard ratio of 0.52 indicates a significant reduction in the risk of disease progression...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
